Consolidating the findings above, this meta-analysis found significant mean differences in CAP, L/S ratio, and MRI-PDFF after treatment, favoring the effect of SGLT-2 inhibitor over that of control especially in NAFLD patients. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.